Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | NAT2 |
| Gene Name: | NAT2 |
| Protein Full Name: | Arylamine N-acetyltransferase 2 |
| Alias: | AAC2; EC 2.3.1.5 |
| Mass (Da): | 33542 |
| Number AA: | 290 |
| UniProt ID: | P11245 |
| Locus ID: | 10 |
| COSMIC ID: | NAT2 |
| Gene location on chromosome: | 8p22 |
| Cancer protein type: | OP/TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 19626 |
| Percent of cancer specimens with mutations: | 0.35 |
| Normal role description: | NAT2 is a N-acetyltransferase involved in the metabolism of xenobiotics and carcinogens. NAT2 can catalyze the N-acetylation of arylamines and hydrazine group and O-acetylation of hydroxylarylamines. NAT2 is predominantly expressed in liver tissue where drug metabolism typically occurs. Polymorphisms in the NAT2 locus have been suggested to contribute to an individual's unique response to drug therapies and susceptibility to carcinogens. Thus the NAT2 has been proposed as a marker to detect susceptibility of patients to drug interactions and susceptibility to specific cancers. Low activity level of NAT2 has been implicated in lung, liver and bladder cancers while rapid acetylating NAT2 has been implicated in astrocytoma or meningioma. |